Ph. Eur. General Notices Chapter - New Structure and Content
The European Pharmacopoeia (Ph. Eur.) Commission adopted a revised version of Ph. Eur. chapter 1. General Notices to provide greater clarity for users.
New structure and content
The revised Ph. Eur. chapter 1 General Notices features new additions such as
- a section on monographs for medicinal products containing chemically defined APIs. This new section also provides information on related substances and impurities.
- a sub-section on “Demonstration of suitability of monographs”.
- a single section concerning monographs on herbal drugs, containing all paragraphs that were previously dispersed throughout the text.
- an explanation of the rounding rule, information on chiral substances and an example of equivalents (in the tests and assay sections).
-
a clarification of the scope of first and second identification series and of alternative identifications.
In addition, the wording and terminology have been further harmonized. For example,
- “medicinal product” is selected instead of “finished product” and “pharmaceutical preparation”.
- “shelf life” and “re-test period” will be used instead of “period of use” and “period of validity”.
The revised Ph. Eur. chapter 1 General Notices will be published in Ph. Eur. Supplement 10.7, available in October 2021 (implementation date: 1 April 2022).
More information can be found in the EDQM Newsroom: Adoption of the revised General Notices chapter.
Related GMP News
11.06.2025Swissmedic differentiates GMP Scope for Manufacturing and Preparation for Administration
28.05.2025A View on the EU Critical Medicines Act to secure Pharma Supply Chains
20.05.2025Summary Data on Registration and Listing of Cosmetic Facilities and Products
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review